News
Tuneable peptide biotech Parabilis files IPO
Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.
News
MSD's Sac-TMT delivers in first phase 3 readout
MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
News
Novartis reveals more data behind Pluvicto expansion bid
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
News
Another LAG-3 setback as Regeneron drug fails phase 3 trial
Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
News
NICE backs stomach cancer, PAH drugs for NHS use
AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
